Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

845
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
845
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

444
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
444
Dementia01:30

Dementia

239
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
239
Neural Regulation01:37

Neural Regulation

40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

755
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
755
Brainstem01:19

Brainstem

3.6K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LAMP2A-dependent chaperone mediated autophagy regulates Notch signaling and controls neural stem cell differentiation.

Cellular and molecular life sciences : CMLS·2026
Same author

PBMC circRNA Profiles Distinguish Atypical From Idiopathic Parkinsonism and Track Clinical Severity Across Syndromes.

Journal of neurochemistry·2026
Same author

Limb apraxia in Parkinson's disease and atypical parkinsonian syndromes: a systematic review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study.

Radiology·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.

Annals of neurology·2026

Related Experiment Video

Updated: Oct 17, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.0K

Parkinsonism and dementia.

Christos Koros1, Leonidas Stefanis2, Nikolaos Scarmeas3

  • 11st Department of Neurology, Aeginition University, Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.

Journal of the Neurological Sciences
|October 13, 2021
PubMed
Summary

Dementia is a significant challenge in parkinsonian disorders, impacting patients and caregivers more than motor symptoms. Research focuses on biomarkers and treatments to improve cognitive outcomes in these conditions.

Keywords:
Atypical parkinsonian syndromesBiomarkersCognitive declineDementiaDementia with Lewy BodiesParkinson's disease

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K

Related Experiment Videos

Last Updated: Oct 17, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.0K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Dementia is a key feature in most parkinsonian disorders, presenting a significant burden.
  • Cognitive decline can be more challenging for patients and caregivers than motor symptoms.
  • Pathogenesis involves protein aggregation (alpha-synuclein, tau, amyloid) and neurotransmitter dysregulation.

Purpose of the Study:

  • To review and summarize current literature on dementia in parkinsonian disorders.
  • To highlight the impact of cognitive decline on patients and caregivers.
  • To discuss pathogenetic mechanisms, diagnostic approaches, and therapeutic targets.

Main Methods:

  • Literature review of studies on dementia in parkinsonian disorders.
  • Analysis of pathogenetic mechanisms, clinical presentation, and diagnostic biomarkers.
  • Examination of current research and clinical trial endpoints related to cognitive outcomes.

Main Results:

  • Cognitive dysfunction in parkinsonian disorders varies widely, from mild impairment to severe dysfunction.
  • Affected cognitive domains can be single (e.g., executive function) or multiple.
  • Novel biomarkers (genetic, fluid, imaging) show promise for diagnosis and staging.
  • Research is increasingly focused on cognitive aspects, with cognitive outcomes as key trial endpoints.

Conclusions:

  • Dementia is a critical and often underestimated aspect of parkinsonian disorders.
  • Understanding pathogenetic mechanisms is crucial for developing effective treatments.
  • Biomarkers and targeted therapies are essential for improving cognitive outcomes and patient quality of life.